Inclusion Criteria:  Population at risk of developing severe COVID-19, defined as either:  Age ≥ 40 years  Age ≥ 18 years and at least one of the following comorbidities: Chronic heart disease without heart failure or proarrhythmic conditions or ventricular arrythmias, diabetes, chronic lung disease, hypertension, chronic kidney disease estimated glomerula filtration rate (GFR)<60 ml/minute, BMI  30 kg/m2. COVID-19 disease confirmed by the presence of SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR) within 5 days prior to inclusion. For women of childbearing age (defined as non-sterile premenopausal women):  Negative pregnancy test and willingness to use contraceptive during the study period (90 days)  ● Provision of informed consent.  Exclusion Criteria:  Current hospitalization Allergy to amantadine hydrochloride, rimantadine or inactive ingredients.  Known history of:  Untreated narrow-angle glaucoma Kidney disease with eGFR < 35 ml/min Heart failure, proarrhythmic conditions, ventricular arrhythmias. Seizures Parkinson's disease Gastric ulcer Liver Disease Hereditary galactose intolerance, lactose intolerance or glucose/galactose malabsorption  Current use of:  Neuroleptics/antipsychotics/ levodopa Anticholinergics Thiazides Concurrent malignancy requiring chemotherapy Pregnancy and breastfeeding